Stifel Nicolaus Increases Stryker (NYSE:SYK) Price Target to $440.00

Stryker (NYSE:SYK) had its price target increased by equities researchers at Stifel Nicolaus from $400.00 to $440.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the medical technology company’s stock. Stifel Nicolaus’ target price would suggest a potential upside of 12.68% from the stock’s current price.

A number of other analysts have also issued reports on SYK. Citigroup boosted their target price on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Robert W. Baird boosted their target price on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Canaccord Genuity Group boosted their target price on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday. JMP Securities reissued a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $416.40.

Stryker Stock Down 0.2 %

SYK stock opened at $390.48 on Wednesday. The firm has a market cap of $148.86 billion, a PE ratio of 41.85, a PEG ratio of 2.68 and a beta of 0.95. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The firm’s 50 day moving average price is $376.55 and its 200-day moving average price is $362.18. Stryker has a one year low of $314.93 and a one year high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 16.34% and a return on equity of 23.07%. During the same quarter last year, the firm posted $3.46 EPS. On average, equities research analysts anticipate that Stryker will post 12.06 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Stryker

Hedge funds and other institutional investors have recently modified their holdings of the stock. Dunhill Financial LLC increased its position in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares during the last quarter. Centennial Bank AR increased its position in shares of Stryker by 106.7% in the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after purchasing an additional 48 shares during the last quarter. Darwin Wealth Management LLC bought a new stake in shares of Stryker in the 3rd quarter worth about $36,000. Activest Wealth Management bought a new stake in shares of Stryker in the 4th quarter worth about $36,000. Finally, Crews Bank & Trust bought a new stake in shares of Stryker in the 4th quarter worth about $39,000. Institutional investors own 77.09% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.